Table 1.

The table shows mean±SD, median (IQR) or absolute number (percentage) for all patients included (n=62). RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; DAS28, Disease Activity Score-28; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; MTX, methotrexate; OD, other conventional synthetic disease-modifying anti-rheumatic drugs than methotrexate. The differences between DAS28 groups were analysed considering p-value<0.05 as statistically significant result.

CharacteristicsADAETN
n=218%n=185%
Female gender, n (%)14064.212969.7
Median age (IQR), years56.0 (46.0-64.0)58.0 (48.0-66.0)
ADR reports572100.0450100.0
Indication for biologic therapy
 Rheumatoid arthritis9041.312768.6
 Psoriatic arthritis4621.13518.9
 Ankylosing spondylitis/axSpA3214.72312.4
 IBDa5022.900.0
Combination therapyb
 Methotrexate6330.37040.2
 Corticosteroids2512.02112.1
 Thiopurines188.710.6
 No combination therapy8741.85933.9
Other3114.94828.2
  • IQR: interquartile range; IBD: inflammatory bowel disease; axSpA: axial spondyloarthritis.

  • aIBD includes Crohn’s disease and ulcerative colitis.

  • bThe overall percentage exceeds 100% since patients can have a combination therapy consisting of one or more drugs.